SCHEMBL14218293

SCHEMBL14218293

C=C[C@@H](O)[C@H](C)[C@@H](C)/C=C/[C@H](C)[C@@H](C)[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19284753 0.76
SCHEMBL19284989 0.76
SCHEMBL19285034 0.76
SCHEMBL23670239 0.76
SCHEMBL19285333 0.76
SCHEMBL23670238 0.76
SCHEMBL19285074 0.76
SCHEMBL30999483 0.76 ALDH1A1 (0.33)
SCHEMBL13430541 0.76
SCHEMBL15850621 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108559-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASES THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE SUPERGEN, INC. 2008-05-08 US disclosed
US-20070254835-A1 COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISORDERS SUPERGEN INC. 2007-11-01 US disclosed
US-7276228-B2 Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase SUPERGEN, INC. (US) 2007-10-02 US disclosed